OptiNose, Inc. (OPTN)
After hours:
Chart Events
Performance Outlook
| Previous Close | 3.5900 |
| Open | 3.5200 |
| Bid | 3.5900 x 800 |
| Ask | 3.8100 x 800 |
| Day's Range | 3.5200 - 3.8200 |
| 52 Week Range | 1.4550 - 4.1400 |
| Volume | |
| Avg. Volume | 234,412 |
| Market Cap | 309.07M |
| Beta (5Y Monthly) | -0.08 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7100 |
| Earnings Date | Mar 01, 2022 - Mar 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.50 |
- Zacks
OptiNose (OPTN) Reports Q2 Loss, Misses Revenue Estimates
OptiNose (OPTN) delivered earnings and revenue surprises of -4.55% and 7.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Optinose Reports Second Quarter 2022 Financial Results and Operational Updates
Company reports second quarter XHANCE net revenue of $20.6 million increased 12% compared to second quarter 2021 Company plans to submit an sNDA for XHANCE as a treatment for chronic sinusitis by the end of 2022 Company expects full year 2022 XHANCE net revenue to be between $85 to $92 million Company expects full year 2022 and operating expenses to be between $129 to $134 million Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE)
- GlobeNewswire
Optinose Announces Reporting Date for Second Quarter 2022 Financial Results
Conference Call and Webcast to be held August 11, 2022, at 8:00 a.m. Eastern TimeYARDLEY, Pa., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the second quarter 2022 and corporate updates, before market open on Thursday, August 11, 2022. Company to Host Conference CallMembers of the Company’s leadership team will host
